Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy

BACKGROUND AND AIM: Vonoprazan as a new acid blocker has more potency and longer lasting acid suppression than proton pump inhibitors. Whether the efficacy of vonoprazan‐based triple therapy is comparable with or even better than that of currently recommended first‐line therapies is still unknown. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Yu‐Tse, Lee, Fu‐Jen, Kuo, Chen‐Ya, Lin, Yang‐Chao, Liang, Kai‐Shun, Tseng, Liang‐Wei, Chen, Yu‐Tsung, Chang, Chi‐Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958340/
https://www.ncbi.nlm.nih.gov/pubmed/36852150
http://dx.doi.org/10.1002/jgh3.12858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958340/
https://www.ncbi.nlm.nih.gov/pubmed/36852150
http://dx.doi.org/10.1002/jgh3.12858

Ejemplares similares